<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> represents about 5% of <z:hpo ids='HP_0000001'>all</z:hpo> malignant lesions of the head and neck </plain></SENT>
<SENT sid="1" pm="."><plain>In this study we retrospectively evaluated clinical presentation, histological subtype and long-term prognosis of 42 patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> involving the craniofacial area </plain></SENT>
<SENT sid="2" pm="."><plain>The mean age at diagnosis was 64 years </plain></SENT>
<SENT sid="3" pm="."><plain>More than half of the patients presented with disseminated disease at multiple sites (55%, n=23) </plain></SENT>
<SENT sid="4" pm="."><plain>In 62% (n=26) the first manifestation was extranodal </plain></SENT>
<SENT sid="5" pm="."><plain>The most common affected region was the oral cavity (65%, n=17) </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment consisted of local therapy, including surgical resection and radiation, as well as chemotherapy with or without local therapy </plain></SENT>
<SENT sid="7" pm="."><plain>Recurrence occurred in 31% (n=13) of the treated patients </plain></SENT>
<SENT sid="8" pm="."><plain>Mean survival after first diagnosis varied from 17 months in patients presenting with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), to 8.5 years in patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The most common histological subtype is <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Standard treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> consists of chemotherapy combined with CD 20 monoclonal antibody, even after total resection of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>There is high risk of <z:e sem="disease" ids="C0442893" disease_type="Disease or Syndrome" abbrv="">systemic disease</z:e> in patients presenting with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and high risk of post therapy recurrence </plain></SENT>
</text></document>